Editas Medicine, Inc. (NASDAQ:EDIT) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Monday.

According to Zacks, “Editas Medicine, Inc. is a genome editing company. It focuses on translating its genome editing technology into a novel class of human therapeutics which enable precise and corrective molecular modification to treat diseases. Editas Medicine, Inc. is based in Cambridge, Massachusetts. “

A number of other equities analysts also recently commented on EDIT. Cann started coverage on Editas Medicine in a report on Monday, July 17th. They set a “market perform” rating for the company. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Editas Medicine in a report on Tuesday, July 18th. J P Morgan Chase & Co set a $27.00 target price on Editas Medicine and gave the company a “hold” rating in a report on Wednesday, August 9th. Barclays PLC started coverage on Editas Medicine in a report on Wednesday, September 6th. They set an “overweight” rating and a $28.00 target price for the company. Finally, ValuEngine upgraded Editas Medicine from a “sell” rating to a “hold” rating in a report on Saturday, September 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, four have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $26.73.

Shares of Editas Medicine (NASDAQ:EDIT) traded up $1.70 during mid-day trading on Monday, reaching $24.38. The company’s stock had a trading volume of 761,900 shares, compared to its average volume of 918,725. The company has a quick ratio of 10.12, a current ratio of 10.12 and a debt-to-equity ratio of 0.19. Editas Medicine has a 12-month low of $13.12 and a 12-month high of $29.20.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings data on Tuesday, November 7th. The company reported ($0.64) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.60) by ($0.04). The company had revenue of $6.28 million during the quarter, compared to the consensus estimate of $2.66 million. Editas Medicine had a negative net margin of 1,127.03% and a negative return on equity of 70.19%. The business’s revenue for the quarter was up 553.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.59) EPS. equities analysts predict that Editas Medicine will post -2.86 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be read at https://www.thecerbatgem.com/2017/11/13/editas-medicine-inc-edit-downgraded-by-zacks-investment-research.html.

In other Editas Medicine news, insider Katrine Bosley sold 16,666 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $20.33, for a total value of $338,819.78. Following the completion of the transaction, the insider now owns 1,414,629 shares in the company, valued at $28,759,407.57. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In the last quarter, insiders sold 43,332 shares of company stock valued at $946,504. 19.40% of the stock is owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the business. IHT Wealth Management LLC bought a new position in Editas Medicine in the second quarter worth $107,000. Great West Life Assurance Co. Can raised its holdings in Editas Medicine by 519.9% in the third quarter. Great West Life Assurance Co. Can now owns 4,959 shares of the company’s stock worth $114,000 after purchasing an additional 4,159 shares in the last quarter. Bank of America Corp DE raised its holdings in Editas Medicine by 72.2% in the first quarter. Bank of America Corp DE now owns 5,936 shares of the company’s stock worth $133,000 after purchasing an additional 2,489 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in Editas Medicine in the second quarter worth $127,000. Finally, Legal & General Group Plc raised its holdings in Editas Medicine by 308.4% in the second quarter. Legal & General Group Plc now owns 8,654 shares of the company’s stock worth $145,000 after purchasing an additional 6,535 shares in the last quarter. Institutional investors and hedge funds own 67.17% of the company’s stock.

About Editas Medicine

Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.

Analyst Recommendations for Editas Medicine (NASDAQ:EDIT)

Receive News & Stock Ratings for Editas Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine Inc. and related stocks with our FREE daily email newsletter.